PathWhiz

Pathway Description

Dipyridamole (Antiplatelet) Action Pathway

Homo sapiens

Drug Action Pathway

Dipyridamole (also known as Persantine) can bind and inhibit cAMP-specific 3',5'-cyclic phosphodiesterase 4D at platelet cell, which prevent the release of arachidonic acid form membrane phospholipids that eventually decreasing thromboxane A2 activity. Dipyridamole can also induce adenylate cyclase activity by releasing prostacyclin, which lead to inhibition of platelet aggregation and increased intraplatelet concentration of cAMP.

References

Dipyridamole (Antiplatelet) Pathway References

Aggrenox. (2009). e-CPS (online version of Compendium of Pharmaceuticals and Specialties). Retrieved June 24, 2009.

Jennings LK, Saucedo JF: Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Curr Opin Cardiol. 2008 Jul;23(4):302-8. doi: 10.1097/HCO.0b013e3283021ad9.

Pubmed: 18520712

Highlighted elements will appear in red.

Highlight Compounds

	Dipyridamole
	Zinc (II) ion

Highlight Proteins

cAMP-specific 3',5'-cyclic phosphodiesterase 4D

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data